| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,987,180 |
|
|
|
Indirect Value
|
$10,231,890 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$60,219,070 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 55.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-12-14 |
4 |
D |
$179.13 |
$1,502,184 |
D/D |
(8,386) |
43,036 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-15 |
4 |
AS |
$462.72 |
$4,013,177 |
D/D |
(8,567) |
23,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-06 |
4 |
AS |
$16.00 |
$137,743 |
D/D |
(8,599) |
3,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-12-16 |
4 |
D |
$272.73 |
$2,536,934 |
D/D |
(9,302) |
19,686 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-30 |
4 |
OE |
$20.32 |
$199,994 |
D/D |
9,483 |
51,422 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-25 |
4 |
OE |
$52.03 |
$520,300 |
D/D |
10,000 |
32,455 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-13 |
4 |
AS |
$399.80 |
$4,117,958 |
D/D |
(10,278) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-30 |
4 |
S |
$21.50 |
$223,119 |
D/D |
(10,317) |
350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-27 |
4 |
AS |
$435.93 |
$4,680,460 |
D/D |
(10,349) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-24 |
4 |
AS |
$20.00 |
$210,740 |
D/D |
(10,537) |
350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-01 |
4 |
OE |
$145.70 |
$2,091,724 |
D/D |
10,544 |
30,814 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, PreclinDevel & Biomol Sci |
• – – |
2005-08-05 |
4 |
S |
$9.42 |
$101,098 |
D/D |
(10,677) |
5,371 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-23 |
4 |
AS |
$25.41 |
$281,389 |
D/D |
(10,988) |
4,297 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-24 |
4 |
S |
$295.09 |
$3,366,092 |
D/D |
(11,407) |
31,973 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-18 |
4 |
D |
$406.93 |
$4,659,349 |
D/D |
(11,450) |
18,834 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-11 |
4 |
S |
$339.33 |
$3,959,204 |
D/D |
(11,646) |
13,527 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-22 |
4 |
S |
$840.53 |
$9,810,082 |
D/D |
(11,665) |
53,100 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-21 |
4 |
D |
$510.02 |
$5,964,174 |
D/D |
(11,694) |
32,256 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-14 |
4 |
D |
$475.56 |
$5,577,368 |
D/D |
(11,728) |
32,517 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-05-08 |
4 |
OE |
$52.03 |
$650,375 |
D/D |
12,500 |
23,880 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-10-31 |
4 |
D |
$20.12 |
$252,526 |
D/D |
(12,551) |
9,647 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-04-13 |
4 |
OE |
$52.03 |
$680,500 |
D/D |
13,079 |
24,459 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-20 |
4 |
D |
$26.09 |
$365,573 |
D/D |
(14,012) |
15,285 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
D |
$451.89 |
$6,620,640 |
D/D |
(14,651) |
21,729 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-29 |
4 |
D |
$23.28 |
$341,820 |
D/D |
(14,683) |
10,667 |
0 |
- |
|
140 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
